




Therapy

Melatonin analogous for cancer treatment

A research group of the Andalusian Public Health Service (SSPA) has developed a Melatonin analogous (Agomelatine) to treat cancer.



Description

Melatonin affects cell proliferation in a variety of tumor cell lines, both in physiological and pharmacological concentrations.

This research group has demonstrated that a melatonin analogue, called agomelatine, inhibits the growth of cell lines of colon cancer in vitro and in vivo, suggesting the oncostatic / cytotoxic role of this compound.



Intellectual Property

This technology is protected by patent.



Aims

This research group is looking to establish a license agreement or agreement for public-private partnership for the development of technology.



Advantages

This pharmaceutical composition may be administered by any suitable method, such as intravenous infusion and oral, topical or parenteral routes. The combined use with other components is proposed, as well as the preparation of a food composition as a nutritional or dietary supplement.



Classification

Area: Therapy

Technology: Drug Delivery

Pathology: Oncology